+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease



Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease



Pulmonary Circulation 2(3): 365-372



This study measured glucose uptake in the right ventricle (RV) of patients with pulmonary hypertension and investigated the relationship to hemodynamics and survival. Myocardial 18F-fluorodeoxy-glucose (FDG) uptake was measured using single-photon positron emission tomography (SPECT) in 24 patients with idiopathic pulmonary arterial hypertension (IPAH) and 43 patients with congenital heart disease (CHD). In both IPAH and CHD-PAH, RV FDG uptake (RV/LV ratio) was associated with pulmonary vascular resistance (PVR). A second SPECT scan was performed in nine patients after 6 months treatment with sildenafil. PVR decreased from 1683±426 to 1207±383 dyn s(-1) cm(-5) (P < 0.05) and cardiac index improved from 2.2±0.2 to 2.8±0.5 L/min/m(2) (P < 0.01). RV/LV FDG uptake decreased from 1.28±0.32 before treatment to 0.99±0.23 (P < 0.05). Survival in the IPAH group with a baseline RV/LV FDG uptake greater than the median value of 1.20 was significantly lower than that of the group with RV/LV FDG uptake below 1.20 (log-rank test, P < 0.05). In contrast, baseline RV/LV FDG was of little informative value in CHD. FDG uptake by the RV reflects the severity of PVR in PAH. Increased RV FDG uptake is a marker of poor prognosis in IPAH and is reduced in patients receiving effective therapy. It could prove useful in the early clinical assessment of novel therapies for PAH.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052225285

Download citation: RISBibTeXText

PMID: 23130105

DOI: 10.4103/2045-8932.101651


Related references

Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. American Heart Journal 162(3): 562-568, 2011

Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients. European Radiology 22(5): 1059-1066, 2012

Pulmonary hypertension/pulmonary arterial hypertension in congenital heart disease and therapy of pulmonary arterial hypertension in children. Deutsche Medizinische Wochenschrift 139 Suppl 4: S166-S170, 2015

Management of pulmonary arterial hypertension associated with congenital heart disease with specific pulmonary arterial hypertension vasoactive drugs combined with transcatheter closure strategy:a case report. Zhonghua Xin Xue Guan Bing Za Zhi 42(11): 963-964, 2015

Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Current Opinion in Cardiology 23(6): 545-554, 2008

Systolic pulmonary artery pressure and heart rate are main determinants of oxygen consumption in the right ventricular myocardium of patients with idiopathic pulmonary arterial hypertension. European Journal of Heart Failure 13(12): 1290-1295, 2012

Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism 58(4): 1156-1164, 2008

Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. Heart and Lung 43(6): 534-540, 2015

Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Annals of the American Thoracic Society 14(5): 682-689, 2017

Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. Respiration; International Review of Thoracic Diseases 79(4): 279-287, 2010

Long-term Outcomes of Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease as Compared With Idiopathic or Heritable Pulmonary Arterial Hypertension Treated With Tadalafil. Chest Journal 140(4): 734a-734b, 2011

Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism. Netherlands Heart Journal 17(9): 334-338, 2009

Relationship between pulmonary arterial resistance and compliance among patients with pulmonary arterial hypertension and congenital heart disease. Journal of Thoracic and Cardiovascular Surgery 152(2): 507-513, 2018

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease. Annals of Thoracic Medicine 9(Suppl 1): S21-S25, 2014

Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung 196(6): 745-753, 2018